Literature DB >> 6252830

Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.

P R Murray.   

Abstract

The activity of cefotaxime, either alone or combined with an aminoglycoside, was determined against 50 isolates of Pseudomonas aeruginosa, of which 50, 33, and 10 were resistant to gentamicin, tobramycin, and amikacin, respectively. Cefotaxime inhibited 34 isolates at a concentration of 16 microgram/ml and all isolates at 128 microgram/ml. The combinations of cefotaxime with gentamicin, tobramycin, and amikacin were synergistic against 30, 17, and 9 isolates, respectively, and no antagonism was observed with any combination. Synergism was obtained at clinically significant antibiotic concentrations for nine isolates with cefotaxime-gentamicin, five isolates with cefotaxime-tobramycin, and nine isolates with cefotaxime-amikacin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6252830      PMCID: PMC283812          DOI: 10.1128/AAC.17.3.474

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro activity of HR 756, a new cephalosporin, against Neisseria gonorrhoeae.

Authors:  P R Murray; J L Christman; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

2.  Analysis of the interactions between piperacillin, ticarcillin, or carbenicillin and aminoglycoside antibiotics.

Authors:  P Chanbusarakum; P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.

Authors:  F A Drasar; W Farrell; A J Howard; C Hince; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

4.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.

Authors:  J M Hamilton-Miller; W Brumfitt; A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

5.  Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.

Authors:  J Klastersky; C Hensgens; L Debusscher
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

6.  In vitro activity of HR 756, a new cephalosporin compound.

Authors:  P M Shah; G Troche; W Stille
Journal:  J Antibiot (Tokyo)       Date:  1978-11       Impact factor: 2.649

7.  Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole.

Authors:  J P Sosna; P R Murray; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

9.  Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.

Authors:  J C Wade; C R Smith; B G Petty; J J Lipsky; G Conrad; J Ellner; P S Lietman
Journal:  Lancet       Date:  1978-09-16       Impact factor: 79.321

  9 in total
  7 in total

Review 1.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

2.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

4.  Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  H Lagast; S H Zinner; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

5.  Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies.

Authors:  P Martino; M Venditti; M C Petti; F Mandelli; P Serra
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

6.  In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.

Authors:  P Angehrn
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

Review 7.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.